

APPLICANTS: Wands et al.

FILED: Herewith

Appendix

In the specification:

On page 1, line 2, after the title, insert:

--This application is a divisional of patent application U.S. Serial Number 09/436,184, filed on November 8, 1999, the entire contents of which is hereby incorporated by reference.--

In the claims:

Cancel claims 1-15, 23-36 and 38.

Add new claims 39-56.

--39. The method of claim 16, wherein said compound is an antibody or fragment thereof which binds to HAAH.--

--40. The method of claim 39, wherein said antibody or fragment thereof binds to an epitope in the catalytic domain of HAAH.--

--41. The method of claim 16, wherein said compound is a single chain Fv molecule.--

--42. The method of claim 16, wherein said compound is a FB50 antibody.--

--43. The method of claim '16, wherein said compound is a FB50 single chain Fv molecule.--

--44. The method of claim 19, wherein said mutation comprises a substitution or deletion of a histidine residue in said catalytic domain of HAAH.--

APPLICANTS: Wands et al.

FILED: Herewith

--45. The method of claim 19, wherein said mutation is located between residues 650-700 of SEQ ID NO:2. --

--46. The method of claim 19, wherein said mutation is a substitution or deletion at residue 675 of SEQ ID NO:2. --

--47. The method of claim 19, wherein said mutation is a substitution or deletion at residue 679 of SEQ ID NO:2.--

--48. The method of claim 19, wherein said mutation is a substitution or deletion at residue 690 of SEQ ID NO:2.--

--49. The method of claim 19, wherein said compound is administered directly into a tumor site.--

--50. The method of claim 19, wherein said compound is administered systemically.--

--51. The method of claim 16, wherein said tumor is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.--

--52. The method of claim 16, wherein said tumor is a cancer of the central nervous system--.

--53. The method of claim 16, wherein said tumor is a hepatocellular carcinoma.--

--54. The method of claim 16, wherein said tumor is a cholangiocarcinoma.--

--55. The method of claim 16, wherein said neoplasm is a glioblastoma--

--56. The method of claim 16, wherein said neoplasm is a neuroblastoma--